Future studies using inducible knockout models could test whether PD‐1 maintains similar niche functions in adult remyelination, with implications for demyelinating disorders, such as multiple sclerosis, where BMP antagonists show therapeutic promise. This evidence concerns the gene PDCD1 and demyelinating disease.